Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has demonstrated significant growth in revenue, with $790 million reported in Q1 2025 and $949 million in Q2 2025, reflecting robust year-over-year increases driven by broadened uptake of Vyvgart in treating generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The introduction of the pre-filled syringe (PFS) format has notably expanded the prescriber base, with around 1,000 PFS prescribers identified, including 150 new prescribers, indicating strong potential for market penetration. In addition, the positive clinical outcomes from studies, particularly in functional improvements noted in the 6-Minute Walk Test, further bolster confidence in the company's innovative pipeline addressing rare autoimmune diseases.

Bears say

Argenx faces significant risks that could adversely impact its financial performance, primarily due to lower-than-expected growth in sales of its lead product, Vyvgart, and potential safety concerns arising from ongoing trials of its therapies. Additionally, the company must contend with the emergence of new competitors and various macroeconomic factors, including foreign exchange fluctuations, inflation, and shipping risks, which may further detract from its revenue forecasts. Ultimately, any R&D, regulatory, or commercial setbacks could undermine investor confidence and negatively affect Argenx's market position and stock performance.

argenx (ARGX) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 18 analysts, argenx (ARGX) has a Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $972.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $972.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.